Get started
Author

Toni Sarapohja

Observed names: Sarapohja T, Sarapohja, Toni, T SARAPOHJA, T Sarapohja, T. Sarapohja, Toni Sarapohja E
Observed institutions: Université Paris-Sud, Lithuanian University of Health Sciences, University of Hull, Université Paris-Saclay, Institut Gustave Roussy, University Hospital Zurich, Orion Corporation (Finland), Tampere University Hospital, Carolina Urologic Research Center, University of Tampere, Orion Corporation (United Kingdom)
ORCID: 0000-0002-1661-0853
Observed ORCID: 0000-0002-1661-0853
OpenAlex ID: A5002714845
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
2019 · Karim Fizazi, Neal Shore, et al. · New England Journal of Medicine · 947
PDF
Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure
2013 · Milton Packer, Wilson Colucci, et al. · JACC Heart Failure · 443
PDF
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
2020 · Karim Fizazi, Neal Shore, et al. · New England Journal of Medicine · 376
PDF
Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation
2008 · Esko Ruokonen, Ilkka Parviainen, et al. · Intensive Care Medicine · 236
PDF
Levosimendan Facilitates Weaning From Cardiopulmonary Bypass in Patients Undergoing Coronary Artery Bypass Grafting With Impaired Left Ventricular Function
2009 · Heidi I. Eriksson, Jouko R. Jalonen, et al. · The Annals of Thoracic Surgery · 131
PDF
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use
2020 · Zoltán Papp, Piergiuseppe Agostoni, et al. · Journal of Cardiovascular Pharmacology · 114
Intravenous Levosimendan vs. Dobutamine in Acute Decompensated Heart Failure Patients on Beta-Blockers
2010 · Claes-Håkan Bergh, Bert Andersson, et al. · European Journal of Heart Failure · 89
Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use
2020 · Zoltán Papp, Piergiuseppe Agostoni, et al. · Cardiac failure review · 73
PDF
Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care: an economic evaluation
2015 · Heidi Turunen, Stephan M Jakob, et al. · Critical Care · 72
PDF
A prospective, double-blind, pilot, randomized, controlled trial of an “embodied” virtual reality intervention for adults with low back pain
2022 · Christopher Eccleston, Emma Fisher, et al. · Pain · 70
Oral Levosimendan in Patients with Severe Chronic Heart Failure—The PERSIST Study
2008 · Markku S. Nieminen, John G.F. Cleland, et al. · European Journal of Heart Failure · 60
PDF
Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
2020 · Karim Fizazi, Neal D. Shore, et al. · Journal of Clinical Oncology · 49
Population Pharmacokinetics of Dexmedetomidine in Critically Ill Patients
2013 · Pyry Antti Välitalo, Tuula Ahtola-Sätilä, et al. · Clinical Drug Investigation · 48
PDF
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial
2021 · Matthew R. Smith, Neal Shore, et al. · European Journal of Cancer · 36
PDF
Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy
2017 · Gerhard Pölzl, Johann Altenberger, et al. · International Journal of Cardiology · 33
Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial
2019 · Ammar Al-Chalabi, Pamela Shaw, et al. · Journal of Neurology Neurosurgery & Psychiatry · 25
PDF
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial
2021 · Merit Cudkowicz, Angela Genge, et al. · The Lancet Neurology · 21
Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).
2019 · Karim Fizazi, Neal D. Shore, et al. · Journal of Clinical Oncology · 21
Effect of Sedation Regimen on Weaning from Mechanical Ventilation in the Intensive Care Unit
2018 · Silvia L. Nunes, Sune Forsberg, et al. · Clinical Drug Investigation · 19
PDF
Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
2020 · Hiroji Uemura, Hisashi Matsushima, et al. · International Journal of Clinical Oncology · 18
PDF
Darolutamide in nonmetastatic, castration-resistant prostate cancer
2019 · Fizazi K, Shore N, et al. · Yearbook of pediatric endocrinology · 18
Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients
2016 · Matti Kivikko, Piero Pollesello, et al. · International Journal of Cardiology · 18
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial
2023 · Karim Fizazi, Neal D. Shore, et al. · European Journal of Cancer · 17
PDF
Body movement as a biomarker for use in chronic pain rehabilitation: An embedded analysis of an RCT of a virtual reality solution for adults with chronic pain
2022 · Sammeli Liikkanen, Mika Mäkinen, et al. · Frontiers in Pain Research · 15
PDF
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
2022 · Martin Bögemann, Neal D. Shore, et al. · European Urology · 14
Works count: 76
Citation count: 3,082
H-index: 19
I10-index: 28
Year
Topic
Type